RemedyRePack Metoprolol Injection Recall: pH Failure Risk
RemedyRePack recalls Metoprolol Tartrate Injection vials due to pH instability. This may affect medication safety. Check your vial lot numbers for affected batches.
Recall notice
Failed pH Specifications: High Out-of-Specification results for pH were obtained during stability testing.
Contact the company
What happened, in plain English
RemedyRePack is recalling Metoprolol Tartrate Injection vials that failed pH stability testing. This could lead to medication safety issues if used as intended. Read more at govinfonow.com/recall/39472-remedyrepack-metoprolol-injection-recall-ph-failure-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/39472-remedyrepack-metoprolol-injection-recall-ph-failure-risk · Updated October 5, 2026 · FDA enforcement record: FDA #D-0245-2019
Cite this page
“RemedyRePack Metoprolol Injection Recall: pH Failure Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/39472-remedyrepack-metoprolol-injection-recall-ph-failure-risk. Based on FDA recall #D-0245-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0245-2019%22&limit=1).
Why it’s dangerous
The vials failed pH stability testing, meaning the medication's acidity level may be unstable. This could affect how the drug works in the body if used improperly.
Who’s affected
People with prescriptions for Metoprolol Tartrate Injection vials from Claris Lifesciences Inc. in North Brunswick, NJ. Those with specific lot numbers are most at risk.
How to tell if you have this one
Check your vial for the lot number: A0A0253 (expires 02/2019) or B0369427-112717 (expires 08/2019). These vials were manufactured by Claris Lifesciences Inc. in North Brunswick, NJ.
- Brand
RemedyRePack- Category
Drug
What to do — step by step
Check Vial Lot Number
Look for lot numbers A0A0253 (expiring 02/2019) or B0369427-112717 (expiring 08/2019) on the vial.
Where it went and when
Where it was distributed
Distributed in New York.
FDA distribution: “1 vial was distributed to a medical facility in Mayville, NY.” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: New York.
Recall timeline
FDA terminated this recall 3 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0245-2019 (October 26, 2018) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0245-2019 to see it in context.
- Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.